The University of Chicago Header Logo

Connection

Thomas Gajewski to Immunotherapy

Back to Details
This is a "connection" page, showing publications Thomas Gajewski has written about Immunotherapy.
Thomas Gajewski
Connection Strength
9.259
Immunotherapy
  1. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.463
  2. Immunotherapy with a sting. Science. 2020 08 21; 369(6506):921-922.
    View in: PubMed
    Score: 0.431
  3. Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295.
    View in: PubMed
    Score: 0.409
  4. Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019 04 17; 7(1):108.
    View in: PubMed
    Score: 0.393
  5. Fast Forward - Neoadjuvant Cancer Immunotherapy. N Engl J Med. 2018 05 24; 378(21):2034-2035.
    View in: PubMed
    Score: 0.369
  6. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 01 05; 359(6371):104-108.
    View in: PubMed
    Score: 0.360
  7. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Adv Exp Med Biol. 2017; 1036:19-31.
    View in: PubMed
    Score: 0.335
  8. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017 Jan; 27(1):96-108.
    View in: PubMed
    Score: 0.334
  9. Manipulating the microbiome to improve the efficacy of immunotherapy. Clin Adv Hematol Oncol. 2016 Jun; 14(6):424-6.
    View in: PubMed
    Score: 0.322
  10. Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Adv Immunol. 2016; 130:75-93.
    View in: PubMed
    Score: 0.314
  11. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res. 2015 Nov 01; 21(21):4774-9.
    View in: PubMed
    Score: 0.307
  12. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine. 2016 Jan; 77:245-7.
    View in: PubMed
    Score: 0.305
  13. Cancer immunotherapy. Curr Opin Immunol. 2013 Apr; 25(2):259-60.
    View in: PubMed
    Score: 0.259
  14. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013 Apr; 25(2):268-76.
    View in: PubMed
    Score: 0.259
  15. Cancer immunotherapy. Mol Oncol. 2012 Apr; 6(2):242-50.
    View in: PubMed
    Score: 0.237
  16. Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell Melanoma Res. 2010 Oct; 23(5):580-1.
    View in: PubMed
    Score: 0.214
  17. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010 Jul-Aug; 16(4):399-403.
    View in: PubMed
    Score: 0.214
  18. Emerging strategies in regulatory T-cell immunotherapies. Clin Adv Hematol Oncol. 2009 Jan; 7(1):1-10; quiz 11-2.
    View in: PubMed
    Score: 0.193
  19. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother. 2009 Aug; 58(8):1351-3.
    View in: PubMed
    Score: 0.192
  20. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5256-61.
    View in: PubMed
    Score: 0.176
  21. PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells. Cancer Immunol Res. 2025 Apr 02; 13(4):547-559.
    View in: PubMed
    Score: 0.149
  22. Targeting molecular pathways to control immune checkpoint inhibitor toxicities. Trends Immunol. 2025 Jan; 46(1):61-73.
    View in: PubMed
    Score: 0.146
  23. Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy. J Immunother Cancer. 2024 Oct 26; 12(10).
    View in: PubMed
    Score: 0.144
  24. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024 Jun 10; 42(6):1032-1050.e10.
    View in: PubMed
    Score: 0.140
  25. Tissue-resident memory T cells in immune-related adverse events: friend or foe? Oncoimmunology. 2023; 12(1):2197358.
    View in: PubMed
    Score: 0.129
  26. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.114
  27. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy). J Transl Med. 2021 06 30; 19(1):278.
    View in: PubMed
    Score: 0.114
  28. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology. 2021 01; 160(2):600-613.
    View in: PubMed
    Score: 0.110
  29. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med. 2020 09 07; 18(1):346.
    View in: PubMed
    Score: 0.108
  30. cDC1 dysregulation in cancer: An opportunity for intervention. J Exp Med. 2020 08 03; 217(8).
    View in: PubMed
    Score: 0.108
  31. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 04; 8(1).
    View in: PubMed
    Score: 0.105
  32. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer. 2020 03; 127:52-66.
    View in: PubMed
    Score: 0.104
  33. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clin Cancer Res. 2019 07 15; 25(14):4202-4210.
    View in: PubMed
    Score: 0.097
  34. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018 03 23; 359(6382):1366-1370.
    View in: PubMed
    Score: 0.091
  35. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018 03; 18(3):139-147.
    View in: PubMed
    Score: 0.090
  36. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16.
    View in: PubMed
    Score: 0.088
  37. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 01; 123(7):1259-1271.
    View in: PubMed
    Score: 0.083
  38. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27; 350(6264):1084-9.
    View in: PubMed
    Score: 0.077
  39. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol. 2015 Aug; 42(4):663-71.
    View in: PubMed
    Score: 0.075
  40. Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 09; 523(7559):231-5.
    View in: PubMed
    Score: 0.075
  41. Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33:445-74.
    View in: PubMed
    Score: 0.073
  42. Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses. Cancer Cell. 2014 Jan 13; 25(1):37-48.
    View in: PubMed
    Score: 0.068
  43. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
    View in: PubMed
    Score: 0.066
  44. Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med. 2012 May 28; 10:108.
    View in: PubMed
    Score: 0.061
  45. Harnessing the immune response. Clin Adv Hematol Oncol. 2012 Jan; 10(1):46-8.
    View in: PubMed
    Score: 0.059
  46. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214.
    View in: PubMed
    Score: 0.059
  47. SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med. 2011 Sep 19; 9:155.
    View in: PubMed
    Score: 0.058
  48. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
    View in: PubMed
    Score: 0.055
  49. Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother. 2007 Sep; 30(6):577-90.
    View in: PubMed
    Score: 0.044
  50. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. J Neuroimmunol. 2006 May; 174(1-2):74-81.
    View in: PubMed
    Score: 0.040
  51. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97.
    View in: PubMed
    Score: 0.039
  52. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr; 54(4):307-14.
    View in: PubMed
    Score: 0.036
  53. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. Bone Marrow Transplant. 2004 Mar; 33(5):491-7.
    View in: PubMed
    Score: 0.034
  54. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). J Transl Med. 2023 07 28; 21(1):508.
    View in: PubMed
    Score: 0.033
  55. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). J Transl Med. 2022 09 04; 20(1):391.
    View in: PubMed
    Score: 0.031
  56. The p815 mastocytoma tumor model. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.4.
    View in: PubMed
    Score: 0.028
  57. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). J Transl Med. 2019 07 22; 17(1):234.
    View in: PubMed
    Score: 0.025
  58. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J Transl Med. 2018 07 21; 16(1):207.
    View in: PubMed
    Score: 0.023
  59. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44.
    View in: PubMed
    Score: 0.023
  60. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24.
    View in: PubMed
    Score: 0.023
  61. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10.
    View in: PubMed
    Score: 0.022
  62. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313.
    View in: PubMed
    Score: 0.021
  63. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.019
  64. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med. 2015 Nov 30; 13:374.
    View in: PubMed
    Score: 0.019
  65. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277.
    View in: PubMed
    Score: 0.018
  66. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
    View in: PubMed
    Score: 0.015
  67. Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med. 2011 May 12; 9:60.
    View in: PubMed
    Score: 0.014
  68. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.